通用名称

solifenacin succinate

儿科标签批准日期

2020/5/26 0:00:00

特定指示/秒

Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 years and older

标签更改摘要

- Safety and effectiveness have been established in pediatric patients aged 2 years and older for the treatment of NDO and the information on this use is discussed throughout the labeling. - Safety and effectiveness have not been established in pediatric patients less than 2 years of age. - Information on dosing, adverse reactions, and clinical trials. - Postmarketing study. - New dosage form.

治疗类别

Neurogenic detrusor overactivity

立法类型

PREA + BPCA

产品说明书链接